ESR1 and breast carcinoma: When we tested whether IL-8 could alter the transcriptional activity of Erα, we found that incubation of ER+/HRG-negative breast cancer cells with an antibody against IL-8 triggered a dramatic, dose-dependent increase in ER transcriptional activity in endocrine-responsive cells, which was more pronounced when combined with E2.